Dr.  Kezheng Peng focuses on intellectual property legal services in the biomedical field, specializing in helping clients address IP issues related to cutting-edge technologies and complex product pipelines. His service scope includes patent filing and portfolio strategy, reexamination and invalidation, third-party observations, freedom-to-operate (FTO) analysis, and intellectual property due diligence. His technical expertise covers nucleic acid or protein-based macromolecular drugs, gene editing tools, omics sequencing, cell therapy, gene therapy, industrial microbiology, diagnostic kits, biomarkers, and the application of artificial intelligence in the medical field.
With extensive experience, Dr. Peng has successfully assisted numerous clients in resolving patent issues across different jurisdictions, including China, the United States, Europe, Japan, and South Korea. He has also helped clients identify and mitigate IP-related risks in various IPO, financing, and transactional projects. His clientele spans a wide range of entities, including large publicly traded companies, investment institutions, emerging startups, universities, and research institutes, giving him extensive experience tailored to different client types.
Before entering the intellectual property field, Dr. Peng conducted scientific research for many years, publishing high-impact studies as a first author in leading international journals in life sciences, medicine, and pharmacology. Leveraging his rich research background, he is able to approach IP issues from the fundamental logic of technology development, providing clients with end-to-end services ranging from patent strategy to intellectual property due diligence.